News
• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...
The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback